Download PDF
Thromb Haemost 1981; 45(03): 211-213
DOI: 10.1055/s-0038-1650172
Original Article
Schattauer GmbH Stuttgart

Platelet Activation in Myeloproliferative Disorders

S Cortelazzo
The Divisione di Ematologia, Ospedale Generale Regionale, Vicenza, Italy
,
P Viero
The Divisione di Ematologia, Ospedale Generale Regionale, Vicenza, Italy
,
T Barbui
The Divisione di Ematologia, Ospedale Generale Regionale, Vicenza, Italy
› Author Affiliations
Further Information

Publication History

Received 05 February 1981

Accepted 12 March 1981

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Beta-thromboglobulin (beta-TG) and platelet factor four (PF4) are specific platelet proteins released when a process of platelet activation occurs.

The present study was undertaken in order to measure beta-TG and PF4 both as absolute plasma value and ratio to platelet number in 69 patients with myeloproliferative disorders (MD). The aim was to establish whether the increase of the two proteins could depend on platelet number or indicated an “in vivo” platelet activation.

In 74% of patients beta-TG was found elevated and PF4 was high in 68% of cases. However in 34.7% and in 31.9% of cases respectively, the elevation of the two platelet markers was correlated to platelet number and the ratio was normal. Only in about one third of cases an “in vivo” platelet activation could be admitted and this finding provides a more rational use of antiaggregating agents.

Keywords

Myeloproliferative disorders - Platelets - Beta-thromboglobulin - Platelet factor four
 

  • References

  • 1 Walsh PN, Murphy S, Barry WE. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thromb Haemostas 1977; 38: 1085-1096
    PubMedGoogle Scholar
  • 2 Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Int Med 1978; 88: 07-11
    CrossrefPubMedGoogle Scholar
  • 3 Cooper B, Schafer AI, Puchalsky D, Handin RI. Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. Blood 1978; 53: 618-626
    PubMedGoogle Scholar
  • 4 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human β-thromboglobulin and platelet factor four. Thromb Res 1978; 12: 851-861
    CrossrefPubMedGoogle Scholar
  • 5 Zahavi J, Kakkar VV. β-thromboglobulin-a specific marker of in vivo platelet release reaction. Thromb Haemostas 1980; 44: 23-29
    PubMedGoogle Scholar
  • 6 Boughton BJ, Allington MJ, King A. Platelet and plasma β-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haemat 1978; 40: 125-132
    CrossrefPubMedGoogle Scholar
  • 7 Schemthaner G, Ludwig H, Silberbauer K. Elevated plasma β-thromboglobulin levels in multiple myeloma and polycythaemia vera. Acta haemat 1979; 62: 219-222
    CrossrefPubMedGoogle Scholar
  • 8 Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-351
    PubMedGoogle Scholar
  • 9 Gunz FW. Hemorrhagic thrombocythemia. A critical review. Blood I 1960; 15: 706-723
    PubMedGoogle Scholar
  • 10 Lazlo J. Myeloproliferative disorders (MPD). Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 1975; 12: 409-432
    PubMedGoogle Scholar
  • 11 Rundles RW. Chronic granulocytic leukemia. In: Williams WJ, Beutler E, Erslev AJ, Rundles RW. eds Hematology. New York: Mc Graw Hill; 1977: 777-796
    Google Scholar
  • 12 Zahavi J, Cella G, Dubiel M, Kakkar VV. The variability of plasma β-thromboglobulin in healthy individuals. Thromb Haemostas 1978; 40: 565-567
    PubMedGoogle Scholar
  • 13 Zahavi J, Jones NAG, Leyton J, Dubiel M, Kakkar VV. Enhanced in vivo platelet “release reaction” in old healthy individuals. Thromb Res 1980; 17: 329-336
    CrossrefPubMedGoogle Scholar